Serina Therapeutics, Inc. (SER) Stock Analysis & Investment Frameworks
Serina Therapeutics, Inc. (SER) stock analysis on Invetso. Review Serina Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Serina Therapeutics, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Serina Therapeutics, Inc. Key Financial Metrics
- Market Cap: $26.55M
- Revenue: $N/A
- ROE: -222.42%
- ROIC: -116.37%
- Dividend Yield: N/A
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Serina Therapeutics, Inc. Investment Frameworks
Invetso analyzes Serina Therapeutics, Inc. (SER) across the following frameworks:
- Serina Therapeutics, Inc. 10Y Growth Potential
- Serina Therapeutics, Inc. Scenario Analysis
- Serina Therapeutics, Inc. Risks & Opportunities
- Serina Therapeutics, Inc. Economic Moat
- Serina Therapeutics, Inc. Business Model
- Serina Therapeutics, Inc. Management
- Serina Therapeutics, Inc. SWOT Analysis
- Serina Therapeutics, Inc. Porter's 5 Forces
- Serina Therapeutics, Inc. PESTLE Analysis
- Serina Therapeutics, Inc. ESG Analysis